LYMPHOMA, B-CELL
Clinical trials for LYMPHOMA, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, B-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Weekly radiation before CAR t shows promise in small lymphoma study
Disease control CompletedThis study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that had come back or not responded to treatment. The goal was to see if this approach is practical and has fewer side effects before patients receive CAR T-cell therapy. The st…
Matched conditions: LYMPHOMA, B-CELL
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
New pill shows promise for hard-to-treat blood cancers in chinese patients
Disease control CompletedThis study tested an oral drug called LOXO-305 in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma whose cancer had returned or not responded to prior treatments. The main goal was to see how many patients had their tumors s…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
Engineered immune cells take on returning blood cancers in early trial
Disease control CompletedThis early-phase study tested a treatment for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and gave…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug duo shows promise against Hard-to-Treat lymphomas
Disease control CompletedThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and shrinks tumors. Some participants received just one of the drugs for comparison. The study…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
PET-Guided strategy may improve outcomes in aggressive lymphoma
Disease control CompletedThis study tested two different chemotherapy combinations (R-ACVBP and R-CHOP) along with the targeted drug rituximab in 222 adults aged 18-59 with an aggressive type of B-cell lymphoma. Participants had 2 or 3 risk factors that make the disease harder to treat. The researchers u…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Lifting weights during chemo: a new way to fight muscle loss?
Symptom relief CompletedThis study looked at whether a 4-month supervised strength training program could help people with lymphoma keep their muscle mass while undergoing chemotherapy. 42 patients were split into two groups: one did resistance training, the other received usual care. The main goal was …
Matched conditions: LYMPHOMA, B-CELL
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated May 18, 2026 12:07 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who were treated with CAR T-cell therapy for certain blood cancers like lymphoma or leukemia. Researchers collected standard medical data to see how often side effects occurred and how the immune system changed over time. The goal was …
Matched conditions: LYMPHOMA, B-CELL
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated May 26, 2026 07:08 UTC